These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37945655)

  • 1. Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
    Ogura R; Ito S; Ueda T; Gabata Y; Sako S; Inoue Y; Yamada T; Konishi H; Fujihara A; Ukimura O
    Sci Rep; 2023 Nov; 13(1):19517. PubMed ID: 37945655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.
    Li C; Wu S; Wang H; Bi X; Yang Z; Du Y; He L; Cai Z; Wang J; Fan Z
    Oncotarget; 2015 Aug; 6(23):19542-51. PubMed ID: 26143634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
    Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
    Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
    Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
    Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
    Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
    Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
    Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating Telomerase
    Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.